Frankfurt CRISPR/Cas Screening Center (FCSC)
The recently introduced CRISPR/Cas technology initiated an unprecedented biological revolution. As such, there is an increasing demand on gene editing technologies, including single and multiple gene knockouts, transcriptional activation/repression, targeted single nucleotide modification or the precise replacement of genetic loci for the purpose of tagging or modification.
To meet the increasing demand within the Institute and the local community, the IBC2 has built up the Frankfurt CRISPR/Cas Screening Center (FCSC). On the basis of collaboration, the platform supports both internal and external researchers with expertise, reagents and strategic advice on gene editing. The FCSC guides researches along their individual needs, ranging from single to multiple gene editing events, specific gene replacements, to the generation of custom-made gRNA libraries.
To generate high-quality gene editing reagents with unprecedented coverage, the FCSC mainly relies on the proprietary 3Cs technology, which was invented at the IBC2. The FCSC also contributes to further development of the technology for new applications.
The FCSC is closely connected with several research networks, including the CRC 1177 on “Molecular and Functional Characterization of Selective Autophagy”, the Excellence Cluster “Cardiopulmonary Institute (CPI)”, Frankfurt Cancer Institute (FCI) and Innovative Medicine Initiative (IMI).
Any requests for collaborations can be addressed to Koraljka Husnjak (+49 69 6301 5820).